Aestus Therapeutics in North Brunswick, New Jersey) and Eisai Inc. in Woodcliff Lake, New Jersey will collaborate on research and development of novel therapeutics for the treatment of psychiatric disorders. The collaboration will cover pre-clinical validation of potential therapeutics leading to clinical proof-of-concept studies.
Aestus says it has previously identified products with the potential to treat certain psychiatric disorders using an analysis it developed of gene expression data sets, with biological pathway mining on data from relevant disease models. The partnership with Eisai will test these products to identify the best candidates for further development in clinical trials.
According to the National Institute of Mental Health, about one in four adults suffer from a diagnosable mental disorder in a given year. A smaller yet still significant proportion — about 6 percent — suffer from a serious mental illness. Mental disorders are also the leading cause of disability in the U.S. and Canada for ages 15-44.
Aestus Therapeutics is a translational medicine company in the field of serious neurological diseases. The company uses genomic data analysis to discover links between these diseases and biological pathways. Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company.
RSS - Posts